This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III NSCLC. Durvalumab significantly improved overall survival, progression free survival, and time to distant metastasis or death.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Other
September 14, 2018
Patient Care and General Interest
3D personalized simulations of patient hearts reportedly allow physicians to better locate and treat arrhythmias.
August 20, 2018
This provocative editorial outlines concepts that thoracic surgeons should understand in the era of immunotherapy for potentially resectable N2 disease.
July 27, 2018
Patient Care and General Interest
July 6, 2018
This retrospective study of 328 patients undergoing resection for non-small cell lung cancer demonstrated that sarcopenia determined by psoas muscle mass on computed tomography was associated with increased postoperative complications and was an independent predictor of survival.
May 31, 2018
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was a marker for patient selection for immunotherapy.
May 30, 2018
The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.
May 23, 2018
The age-specific incidence of non-small cell lung cancer has reversed in individuals born since the 1960s, with women now having a higher incidence than men. This trend is not explained by differences in smoking habits.
May 23, 2018
This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer. The safety profile was adequate, 20 of 21 patients underwent complete resection, and the pathologic major response rate was 45%. The response was similar regardless of PD-L1 status, and response was related to
May 23, 2018
Using eight computed tomography radiographic features in an automated algorithm, differentiating between benign and malignant status of indeterminate pulmonary nodules had an area under the curve of 0.939.